CytomX Therapeutics, Inc.
CTMXHealthcare|Biotechnology|US
$2.19
+0.05 (+2.34%)
Tangible Book / Share
$1.29
Cash / Share
$1.59
Clinical Trials (10)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06265688 First In Human Study of CX-2051 in Advanced Solid Tumors | Solid Tumor, Adult | P1 | Recruiting | 160 | Open-label | CX-2051, Bevacizumab |
| NCT06462794 First In Human Study of CX-801 in Advanced Solid Tumors | Solid Tumor, Adult | P1 | Recruiting | 121 | Open-label | CX-801, pembrolizumab |
| NCT03543813 PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | Solid Tumor, Adult, Head and Neck Cancer | P1P2 | Completed | 133 | Open-label | CX-2029 |
| NCT07900165 Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer | Colo-rectal Cancer | P1P2 | Not Yet Recruiting | 368 | Open-label | varsetatug masetecan, bevacizumab + 5-FU + leucovorin, bevacizumab |
| NCT04596150 Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer | Neoplasms, Breast Neoplasms | P2 | Completed | 125 | Open-label | CX-2009, CX-072 |
| NCT03993379 PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors | Solid Tumor, Unresectable or Metastatic Melanoma | P2 | Terminated | 3 | Open-label | CX-072, Ipilimumab |
| NCT03149549 PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | Solid Tumor, Adult, Breast Cancer | P1P2 | Terminated | 99 | Open-label | CX-2009 |
| NCT03013491 PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas | Solid Tumor, Lymphoma | P1P2 | Terminated | 196 | Open-label | CX-072, ipilimumab, vemurafenib |
| NCT03706274 PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors | Solid Tumor, Adult | P1 | Withdrawn | — | Open-label | CX-188 |
| NCT05387265 A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors | Solid Tumors | P1 | Terminated | 83 | Open-label | CX-904 |